Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy
Open Access
- 15 May 2014
- journal article
- case report
- Published by Springer Science and Business Media LLC in BMC Pulmonary Medicine
- Vol. 14 (1), 83
- https://doi.org/10.1186/1471-2466-14-83
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2014
- Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangementLung Cancer, 2014
- Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular CoagulationJournal of Thoracic Oncology, 2013
- Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRASCancer, 2009
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung CancersJournal of Thoracic Oncology, 2008